Novel Drug Approvals for 2022

… in cold agglutinin disease Drug Trials Snapshot 4. Vabysmo faricimab-svoa 1/28/2022 To treat neovascular (wet) …

Bispecific Antibodies: An Area of Research and Clinical Applications

… form of unresectable or metastatic uveal melanoma Vabysmo faricimab-svoa 2022 To treat neovascular (wet) age-related …

New Drug Therapy Approvals 2022

… Terlivaz terlipressin Tzield teplizumab-mzwv Vabysmo faricimab-svoa Vivjoa oteseconazole Vonjo pacritinib Voquezna … of Stage 3 type 1 diabetes Injection 1/28/2022 Vabysmo faricimab-svoa To treat neovascular (wet) aged-related …

Drug Trials Snapshots: VABYSMO

… for additional uses of the drug (if applicable). VABYSMO (faricimab-svoa) vuh-biz-moe Genentech, Inc. Original Approval …

Drug Trials Snapshots

… tract infection (abbreviated as cUTI) Vabomere VABYSMO faricimab-svoa January 28, 2022 To treat neovascular (wet) …

CDER Priority Drug and Biologic Approvals in Calendar Year 2022

… IMMUNOCORE LIMITED P,O 1/25/2022 BLA 761235 VABYSMO FARICIMAB-SVOA GENENTECH, INC. P 1/28/2022 CY 2022 CDER Drug …

CDER New Molecular Entity (NME) and Original Biologic Approvals Calendar Year 2022

… OR METASTATIC UVEAL MELANOMA. BLA 761235 VABYSMO FARICIMAB-SVOA GENENTECH, INC. P 1/28/2022 FOR THE TREATMENT …

CDER Drug and Biologic Approvals for Calendar Year 2022

… IMMUNOCORE LIMITED P,O 1/25/2022 BLA 761235 VABYSMO FARICIMAB-SVOA GENENTECH, INC. P 1/28/2022 BLA 761164 ENJAYMO …

New Drug Application (NDA) and Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals: 2023

… BLA 761235 1 Labeling Change With Clinical Data VABYSMO (FARICIMAB-SVOA) GENENTECH, INC. S 1/27/2023 BLA 761224 1 … LLC S 10/23/2023 BLA 761235 3 New Indication VABYSMO (FARICIMAB-SVOA) GENENTECH, INC. S 10/26/2023 BLA 125118 250 …

Novel Drug Approvals for 2022

… Terlivaz terlipressin Tzield teplizumab-mzwv Vabysmo faricimab-svoa Vivjoa oteseconazole Vonjo pacritinib Voquezna …

FDA FOIA Closed Log - February 2025

… 2022-1981 Genentech Entire unredacted SBA for Vabysmo (faricimab-svoa), BLA 761235, for the indication of treatment …